1. Home
  2. YJ vs BIVI Comparison

YJ vs BIVI Comparison

Compare YJ & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.60

Market Cap

9.1M

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.32

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YJ
BIVI
Founded
2015
2013
Country
China
United States
Employees
N/A
13
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
10.4M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
YJ
BIVI
Price
$1.60
$1.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.3K
91.1K
Earning Date
03-27-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.88
52 Week High
$2.67
$9.09

Technical Indicators

Market Signals
Indicator
YJ
BIVI
Relative Strength Index (RSI) 42.84 39.83
Support Level $1.43 $1.14
Resistance Level $1.68 $1.32
Average True Range (ATR) 0.10 0.11
MACD -0.03 -0.03
Stochastic Oscillator 0.00 9.82

Price Performance

Historical Comparison
YJ
BIVI

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: